



Universiteit  
Leiden  
The Netherlands

## **Apo-calypse now? Apolipoprotein profiling to reduce residual cardiovascular disease**

Reijnders, E.

### **Citation**

Reijnders, E. (2025, October 30). *Apo-calypse now?: Apolipoprotein profiling to reduce residual cardiovascular disease.*


Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from:

**Note:** To cite this publication please use the final published version (if applicable).

# CHAPTER 6



# Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients who Benefit from Targeted PCSK9i Therapy

E. Reijnders<sup>1</sup>, P.M. Bossuyt<sup>2</sup>, J.W. Jukema<sup>3,4</sup>, L.R. Ruhaak<sup>1</sup>, F.P.H.T.M. Romijn<sup>1</sup>, M. Szarek<sup>5,6,7</sup>, S. Trompet<sup>8</sup>, D.L. Bhatt<sup>9</sup>, V.A. Bittner<sup>10</sup>, R. Diaz<sup>11</sup>, S. Fazio<sup>12</sup>, I. Stevanovic<sup>13</sup>, S.G. Goodman<sup>14</sup>, R.A. Harrington<sup>15</sup>, H.D. White<sup>16</sup>, P.G. Steg<sup>17</sup>, G.G. Schwartz<sup>5</sup>, C.M. Cobbaert<sup>1</sup>

<sup>1</sup>Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, The Netherlands

<sup>2</sup>Department of Epidemiology and Data Science, Amsterdam UMC, The Netherlands

<sup>3</sup>Department of Cardiology, Leiden University Medical Center, The Netherlands

<sup>4</sup>Netherlands Heart Institute, Utrecht, The Netherlands

<sup>5</sup>Division of Cardiology, University of Colorado School of Medicine, Aurora, USA

<sup>6</sup>CPC Clinical Research, Aurora, CO, USA

<sup>7</sup>State University of New York, Downstate Health Sciences University, Brooklyn, USA

<sup>8</sup>Department of Internal Medicine, Leiden University Medical Center, The Netherlands

<sup>9</sup>Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>10</sup>Division of Cardiovascular Disease, University of Alabama at Birmingham, USA

<sup>11</sup>Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina

<sup>12</sup>Regeneron Pharmaceuticals, Tarrytown, NY, USA

<sup>13</sup>Sanofi, Paris, France

<sup>14</sup>Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, and St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

<sup>15</sup>Weill Cornell Medicine, New York, NY, USA

<sup>16</sup>Green Lane Cardiovascular Research Unit, Te Whatu Ora—Health New Zealand, Te Toka Tumai, and University of Auckland, New Zealand

<sup>17</sup>Université Paris-Cité, INSERM-UMR1148, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, and Institut Universitaire de France, Paris, France



## CLINICAL PERSPECTIVE

### What is new?

- Models to predict major adverse cardiovascular event (MACE) and all-cause death in patients with recent ACS based on an apolipoprotein panel were developed and compared to models based on the conventional lipid panel.
- Apolipoprotein profiling led to better prognostic performance for MACE and all-cause death than the conventional lipid panel.
- Models using the baseline apolipoprotein panel to estimate risk of MACE and all-cause death also predict treatment benefit of alirocumab on those outcomes, thus allowing treatment benefit to be estimated in individual patients, enabling personalized medicine.

### What are the clinical implications?

- In patients on optimized statin treatment, an integrated serum apolipoprotein panel significantly improved the estimation of residual cardiovascular risk compared with the conventional lipid panel.
- The apolipoprotein panel has potential to improve health outcomes in patients with ACS by guiding the identification and treatment of those most likely to benefit from additional lipid-lowering drugs such as alirocumab, thus potentially reducing healthcare costs.

## INTRODUCTION

In individuals with dyslipidemia and coronary artery disease, considerable residual risk of cardiovascular events persists despite optimized statin treatment.<sup>1, 2</sup> Some of this residual risk is attributable to persistent lipoprotein abnormalities. However, estimation of that risk from a conventional lipid panel, including TC, high-density lipoprotein cholesterol (HDL-C), LDL-C, and triglyceride levels, may not be fully quantified.<sup>1, 3-5</sup> There is a clear unmet clinical need for more refined phenotyping of dyslipidemia to improve risk prediction and guide treatment decisions in the management of dyslipidemia.<sup>6</sup>

Apolipoproteins, the functional proteins of lipid metabolism, might be a missing link to fulfill this unmet clinical need.<sup>6, 7</sup> Over recent years, apolipoproteins have gained recognition as significant biomarkers for cardiovascular disease.<sup>6, 8</sup> Notably, apolipoprotein B (ApoB), found on all atherogenic lipoprotein particles, was shown to clinically and metrologically outperform traditional markers such as LDL-C.<sup>9-11</sup> In addition, ApoB is reported to be equivalent or even better of a predictor of cardiovascular events than non-HDL-C.<sup>9-14</sup> Apo(a), associated with the genetically determined risk factor lipoprotein(a), and ApoC-III, an inhibitor of triglyceride-rich lipoprotein clearance, have also become important markers in cardiovascular research.<sup>15-17</sup> Therapies targeting ApoB, Apo(a), and ApoC-III have been, or are currently being developed,<sup>18-23</sup> and therapies targeting other apolipoproteins may lie ahead. Consequently, measuring a panel of apolipoproteins may be valuable for both diagnostic purposes and for selecting patients for advanced lipid-lowering therapies.

Pechlaner *et al.* and Clarke *et al.* have reported that a panel of apolipoproteins measured by mass spectrometry could help predict cardiovascular events.<sup>24, 25</sup> To date, however, the clinical effectiveness of an apolipoprotein multimarker panel has not yet been demonstrated.

We developed a mass spectrometry-based multiplex apolipoprotein panel test, which is currently comprised of Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB, ApoC-I, ApoC-II, ApoC-III and ApoE quantification as well as ApoE phenotyping.<sup>26-28</sup> To implement the apolipoprotein panel test as a new medical test, we relied on the test evaluation framework, developed by the European Federation of Clinical Chemistry and Laboratory Medicine Working Group Test Evaluation<sup>29</sup>. Since analytical performance validation of the apolipoprotein panel has been completed<sup>26, 30</sup>, showing accuracy and robustness over time<sup>28</sup>, we undertook an evaluation of its clinical performance and clinical effectiveness in a large, post-ACS cohort of patients on high-intensity statin therapy.

Accordingly, the goal of the current post hoc analysis of the ODYSSEY OUTCOMES trial was to compare performance of the apolipoprotein panel versus the conventional lipid panel in predicting major adverse cardiovascular events (MACE) and all-cause death, as well the treatment benefit of alirocumab, a PCSK9 inhibitor, on MACE.

## METHODS

Requests from qualified investigators for data from the ODYSSEY OUTCOMES Trial will be considered by its Executive Steering Committee and the sponsor and should be submitted to [odysseyoutcomesesc@gmail.com](mailto:odysseyoutcomesesc@gmail.com).

### Study design

The design<sup>31</sup>, primary results<sup>32</sup>, and total events analyses<sup>33</sup> from the ODYSSEY OUTCOMES Trial (NCT01663402) have been published. In brief, 18,924 patients from 1,315 sites across 57 countries were randomized in a 1:1 ratio to receive either alirocumab (75 mg, increased to 150 mg for those who did not achieve an LDL-C level  $<1.29$  mmol/L (50 mg/dL)) or matching placebo, administered subcutaneously every 2 weeks. Key inclusion criteria were recent hospitalization (1 to 12 months prior to randomization) due to ACS (myocardial infarction or unstable angina), and an LDL-C level  $\geq 1.81$  mmol/L (70 mg/dL), a non-HDL-C level  $\geq 2.59$  mmol/L (100 mg/dL), and/or ApoB  $\geq 0.80$  g/L on treatment with atorvastatin (40 to 80 mg daily), rosuvastatin (20 to 40 mg daily), or the maximum tolerated dose of either statin. A triglyceride level  $\geq 4.52$  mmol/L (400 mg/dL) at the screening visit was exclusionary. The trial was approved by the responsible institutional review board at each participating site. Informed consent was obtained from all participants.

### Patient Outcomes

The primary efficacy outcome of the trial and of the current analysis was first occurrence of MACE, comprising death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization.<sup>32</sup> Additionally, we analyzed the incidence of all-cause death.<sup>32</sup> All events included in the analyses were adjudicated by an independent committee blinded to treatment assignment.

### Measurement of the conventional lipid panel

The conventional lipid panel, including total, LDL, and HDL cholesterol and triglycerides, was measured centrally at Covance Laboratories. LDL-C levels were calculated using the Friedewald formula<sup>34</sup>, except when triglyceride levels exceeded 4.52 mmol/L (400 mg/dL) or when the calculated LDL-C level was  $<0.39$  mmol/L (15 mg/dL). In these cases, LDL-C was assessed by preparative ultracentrifugation and  $\beta$  quantification.

### Measurement of serum apolipoproteins

Serum apolipoprotein Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB (reflecting total ApoB including ApoB48 and ApoB100), ApoC-I, ApoC-II, ApoC-III, ApoE levels including ApoE phenotype were

measured with a semi-automated lab-developed multiplex test by liquid chromatography tandem mass spectrometry (LC-MS/MS) (1290 Infinity II UHPLC coupled to 6495 QQQ-MS Agilent Technologies, Santa Clara, CA, USA). The analytical method has been published for seven apolipoproteins.<sup>26, 30</sup> In brief, sample pre-analysis was performed semi-automatically on a 96-channel Agilent BRAVO automated liquid handling platform. Thereafter, samples were either stored overnight at -80 °C with solid-phase extraction the next day or immediately subjected to solid-phase extraction after quenching. Subsequently, the samples were measured on the mass spectrometer. More specific details on the process, the measurements, and the quality of the data have been published.<sup>35</sup>

## Statistical analysis

Patients without available baseline samples for apolipoprotein levels were excluded from the current analyses, including those recruited from countries or sites where additional exploratory laboratory testing was not permitted or not possible. Apolipoproteins were also measured in available month 4 samples on assigned treatment.

Distributions of apolipoproteins at baseline are described by treatment group, along with the absolute and percentage change from baseline to month 4 (122±28 days) after randomization. The first measurement result was analyzed if a patient had multiple measurements within the time frame. For statistical analyses, Apo(a) concentrations below the lower limit of quantification (3.8 nmol/L) were set to the midpoint between 0 and the lower limit of quantification (1.9 nmol/L). Median apolipoprotein levels for baseline and month 4 serum samples were calculated for each treatment arm, including both the absolute and percentage changes from baseline to month 4.

To evaluate prognostic performance, logistic regression modeling with restricted cubic splines was used to estimate the probabilities of a MACE and all-cause death based on continuous baseline biomarker concentrations within the placebo group. Three models were constructed, based on, respectively, (1) baseline apolipoprotein concentrations including the ApoE phenotype, (2) baseline conventional lipid concentrations including TC, HDL-C, and triglycerides, and (3) both baseline apolipoprotein concentrations, the ApoE phenotype and conventional lipid concentrations. LDL-C was not included in the models, as it is calculated using the Friedewald formula based on TC, HDL-C, and triglycerides, making its inclusion redundant. Direct and calculated LDL-C values also tend to be inaccurate, especially at lower levels under conditions of intensive lipid-lowering treatment.<sup>6, 11, 36</sup> The ApoE phenotype, was added as a categorical variable with six possible phenotypes (E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4). The significance of non-linear effects, necessitating the use of splines, was assessed using Wald tests. Four knots were used for all biomarkers, in accordance with standard practice.<sup>37</sup> For Apo(a), three knots were applied due to its highly skewed

distribution (Supplemental Figure S1). We used partial Wald tests for testing the partial effect of each of the apolipoproteins, adjusted for the other variables in the model.

We calculated the area under the empirical receiver operating characteristic curve (AUC) with 95% CI for each model as an expression of the prognostic performance. We compared the performance of the combined model relative to the model based on conventional lipids only using the generalized likelihood ratio test. Additionally, we compared the ROC curves of the apolipoprotein panel with those of the lipid panel using the DeLong test.

Additionally, two models were built to quantify the incremental value of apolipoproteins after accounting for demographic and clinical information. The first model included age, sex, ethnicity, body mass index, smoking status, and history of diabetes, while the second model added the apolipoprotein panel to these parameters. The models were compared using the generalized likelihood ratio test.

To evaluate predictive performance, the same prognostic modeling strategy was applied for the alirocumab treatment arm, to estimate the probabilities of a MACE and all-cause death with alirocumab. This resulted in three pairs of models, one for each treatment arm, based on baseline apolipoprotein concentrations, baseline conventional lipids, and the combination of the two.

Placebo and alirocumab models were then run on the full study group to generate two estimated probabilities of an event per patient, based on that patient's profile of baseline values: one for the likelihood of the event if in the placebo group and another for the likelihood of that event if in the alirocumab group. The treatment effect was calculated as the difference between both probabilities. The threshold for a treatment benefit was set based on an absolute risk reduction of MACE of 2.1% and for all-cause death of 0.7%.

P values <0.05 from 2-sided tests were considered statistically significant. Analyses were conducted using R version 4.3.2.

## RESULTS

### Baseline characteristics

A total of 11,843 participants had baseline conventional lipid and apolipoprotein measurements and formed the analysis cohort, which is a subcohort from the original ODYSSEY OUTCOMES cohort. Baseline characteristics are shown in Table 1. Median age was 58 years, 24% were female, and 81% were White. Over 95% of patients received statin therapy at randomization; 89% received high-intensity statin therapy. Median ApoB at baseline was 0.80 g/L (interquartile range 0.69-0.96 g/L) median LDL-C at baseline was 2.24 mmol/L (86.49 mg/dL) (interquartile range 1.89-2.70 mmol/L (73.00-104.40 mg/dL)). Distribution plots of baseline apolipoprotein levels of the ODYSSEY OUTCOMES study group are depicted in Supplemental Figure S1.

**Table 1: Demographic and Baseline Clinical Characteristics of the Study Group by Treatment Assignment**

| Characteristics                                                  | Alirocumab<br>(n = 5,917) | Placebo<br>(n = 5,926) |
|------------------------------------------------------------------|---------------------------|------------------------|
| <b>Demographics</b>                                              |                           |                        |
| Age, y                                                           | 58 (51, 65)               | 58 (52, 65)            |
| Male sex                                                         | 4500 (76.1)               | 4492 (75.8)            |
| <b>Ethnicity</b>                                                 |                           |                        |
| White                                                            | 4775 (80.1)               | 4823 (80.7)            |
| Asian                                                            | 719 (12.1)                | 721 (12.1)             |
| Black or African American                                        | 167 (2.8)                 | 157 (2.6)              |
| Unknown                                                          | 5 (0.1)                   | 2 (0)                  |
| <b>Medical history</b>                                           |                           |                        |
| Hypertension                                                     | 3796 (63.7)               | 3731 (62.4)            |
| Diabetes                                                         | 1741 (29.2)               | 1788 (29.9)            |
| Current tobacco smoker                                           | 1434 (24.1)               | 1450 (24.3)            |
| Time from index ACS to randomization, months                     | 2.6 (1.7, 4.5)            | 2.7 (1.7, 4.5)         |
| <b>Background lipid-lowering therapy</b>                         |                           |                        |
| High-intensity statin                                            | 5275 (88.5)               | 5347 (89.5)            |
| Low- or moderate intensity statin                                | 485 (8.1)                 | 446 (7.5)              |
| No statin or other lipid-lowering therapy                        | 75 (1.3)                  | 78 (1.3)               |
| Only non-statin lipid-lowering therapy                           | 127 (2.1)                 | 106 (1.8)              |
| <b>Baseline biometric and laboratory data</b>                    |                           |                        |
| Body mass index, kg/m <sup>2</sup>                               | 28.1 (25.4, 31.3)         | 28 (25.2, 31.2)        |
| Systolic blood pressure, mm Hg                                   | 127 (118, 138)            | 126 (116, 138)         |
| Hemoglobin A1c, %                                                | 5.8 (5.5, 6.3)            | 5.8 (5.5, 6.4)         |
| High-sensitivity C-reactive protein, mg/dL                       | 0.2 (0.1, 0.4)            | 0.2 (0.1, 0.4)         |
| Estimated glomerular filtration rate, mL/min/1.73 m <sup>2</sup> | 77.9 (67.2, 90.1)         | 78.2 (67.4, 90.5)      |
| <b>Conventional lipid panel</b>                                  |                           |                        |
| Total cholesterol (mmol/L)                                       | 4.12 (3.67, 4.72)         | 4.14 (3.67, 4.73)      |
| High-density lipoprotein cholesterol, mmol/L                     | 1.09 (0.93, 1.29)         | 1.09 (0.93, 1.29)      |
| Low-density lipoprotein cholesterol, mmol/L                      | 2.24 (1.89, 2.69)         | 2.24 (1.89, 2.72)      |
| Triglycerides, mmol/L                                            | 1.46 (1.07, 2.06)         | 1.48 (1.07, 2.1)       |
| Non-high-density lipoprotein cholesterol, mmol/L                 | 2.97 (2.56, 3.54)         | 3 (2.57, 3.57)         |
| <b>Apolipoprotein panel</b>                                      |                           |                        |
| Apolipoprotein(a), nmol/L                                        | 41.1 (14.4, 140.1)        | 43.0 (14.3, 146.2)     |
| Apolipoprotein B, g/L                                            | 0.80 (0.69, 0.95)         | 0.80 (0.69, 0.96)      |
| Apolipoprotein A-I, g/L                                          | 1.20 (1.06, 1.37)         | 1.20 (1.06, 1.36)      |
| Apolipoprotein A-II, mg/L                                        | 246 (217, 280)            | 244 (216, 279)         |
| Apolipoprotein A-IV, mg/L                                        | 182 (145, 224)            | 181 (144, 223)         |
| Apolipoprotein C-I, mg/L                                         | 16.0 (13.0, 19.0)         | 16.0 (13.0, 19.0)      |
| Apolipoprotein C-II, mg/L                                        | 34.0 (26.0, 44.0)         | 34.0 (26.0, 45.0)      |
| Apolipoprotein C-III, mg/L                                       | 85.0 (65.0, 112.0)        | 86.0 (65.0, 114.0)     |
| Apolipoprotein E, mg/L                                           | 23.0 (19.0, 28.0)         | 23.0 (19.0, 28.0)      |
| ApoE2/E2                                                         | 17 (0.3)                  | 12 (0.2)               |
| ApoE2/E3                                                         | 310 (5.2)                 | 298 (5.0)              |
| ApoE2/E4                                                         | 72 (1.2)                  | 69 (1.2)               |
| ApoE3/E3                                                         | 3826 (64.7)               | 3917 (66.1)            |
| ApoE3/E4                                                         | 1551 (26.2)               | 1506 (25.4)            |
| ApoE4/E4                                                         | 141 (2.4)                 | 124 (2.1)              |

Values are medians (interquartile range) for continuous variables and n (%) for categorical variables.

## The Effect of Alirocumab on Apolipoprotein Levels

The effect of alirocumab on apolipoprotein levels was evaluated by examining changes from baseline to four months after randomization (Table 2). Alirocumab treatment led to a reduction in apolipoproteins associated with ApoB-containing lipoprotein particles including decreased levels of Apo(a), ApoB, ApoC-I, ApoC-II, ApoC-III, and ApoE.

## Prognostic Performance

Participants were followed for cardiovascular events for a median of 2.9 years (interquartile range 2.4-3.5). A MACE event was experienced by 721 (12.2%) in the placebo group and 596 (10.1%) in the alirocumab group ( $p < 0.0005$ ). All-cause death was experienced by 250 (4.2%) patients in the placebo group and 208 (3.5%) in the alirocumab group.


Spline analysis revealed associations between baseline apolipoproteins and the incidence of MACE events and all-cause death (Supplemental Figure S2 and S3). Apo(a), ApoB, and ApoC-III exhibited a generally linear relationship where higher levels of these apolipoproteins were associated with higher odds of experiencing a MACE event or all-cause death. In contrast, ApoA-II and ApoC-II showed an inverse linear relationship with the odds of these events. ApoA-IV demonstrated a J-shape pattern with all-cause death, indicating that both low and high levels were associated with increased odds, whereas its relationship with MACE appeared more linear. ApoC-I showed a linear relationship with MACE and an inverse J-shape relationship with all-cause death. For ApoE, an inverse J-shape pattern was observed with both MACE and all-cause death, suggesting that both low and high levels were associated with decreased odds of these events.

The apolipoprotein panel model was prognostic for MACE, with an AUC of 0.648 (95% CI 0.626, 0.670). The apolipoprotein panel was prognostic for all-cause death as well, with an AUC of 0.699 (95% CI 0.664, 0.733). In comparison, the prognostic model based on the conventional lipid panel had a lower AUC for MACE (0.579; 95%CI 0.557, 0.602) and for all-cause death (0.599; 95%CI 0.564, 0.635). The apolipoprotein panel had significantly better prognostic performance than the lipid panel for both MACE and all-cause death ( $p < 0.0001$ ). Adding the apolipoprotein panel significantly improved performance of the conventional lipid panel ( $p < 0.0001$  for both MACE and all-cause death). With both lipids and apolipoproteins in a single model the AUC for MACE increased to 0.659 (95% CI 0.637, 0.681) and to 0.732 (95% CI 0.691, 0.756) for all-cause death.

Table 2: Baseline, month 4 and absolute and percentile change from baseline to month 4 in apolipoprotein concentrations by treatment group.

| Protein        | Baseline              |                       | Month 4              |                       | Absolute change baseline to month 4 |                       | Percentage change baseline to month 4 |                      |
|----------------|-----------------------|-----------------------|----------------------|-----------------------|-------------------------------------|-----------------------|---------------------------------------|----------------------|
|                | Alirocumab            | Placebo               | Alirocumab           | Placebo               | Alirocumab                          | Placebo               | Alirocumab                            | Placebo              |
| Apo(a), nmol/L | 41.1<br>(14.4, 140.1) | 43.0<br>(14.3, 146.2) | 23.7<br>(7.6, 107.6) | 37.1<br>(12.0, 134.1) | -10.8<br>(-29.0, -2.8)              | -1.5<br>(-10.4, 3.5)  | -28.1<br>(-48.1, -9.8)                | -4.2<br>(-20.1, 9.9) |
| ApoA-I, g/L    | 1.20<br>(1.06, 1.37)  | 1.20<br>(1.06, 1.36)  | 1.27<br>(1.13, 1.45) | 1.23<br>(1.08, 1.39)  | 0.07<br>(-0.04, 0.18)               | 0.02<br>(-0.08, 0.13) | 6.1<br>(-3.1, 15.9)                   | 1.8<br>(-6.7, 11.3)  |
| ApoA-II, mg/L  | 246<br>(217, 280)     | 244<br>(216, 279)     | 253<br>(225, 287)    | 250<br>(221, 284)     | 7<br>(-15, 29)                      | 5<br>(-17, 27)        | 2.7<br>(-5.8, 12.4)                   | 2.0<br>(-6.6, 11.3)  |
| ApoA-IV, mg/L  | 182<br>(145, 224)     | 181<br>(144, 223)     | 190<br>(152, 234)    | 188<br>(152, 233)     | 8<br>(-22, 41)                      | 8<br>(-23, 39)        | 4.7<br>(-11.4, 24.5)                  | 4.7<br>(-11.6, 23.5) |
| ApoB, g/L      | 0.80<br>(0.69, 0.95)  | 0.80<br>(0.69, 0.96)  | 0.38<br>(0.30, 0.52) | 0.81<br>(0.69, 0.98)  | -0.41<br>(-0.53, -0.28)             | 0.01<br>(-0.09, 0.11) | -52.5<br>(-62.0, -38.5)               | 1.1<br>(-10.4, 15.0) |
| ApoC-I, mg/L   | 16<br>(13, 19)        | 16<br>(13, 19)        | 14<br>(11, 17)       | 16<br>(13, 19)        | -2<br>(-4, 0)                       | 0<br>(-2, 0)          | -13.3<br>(-25.0, 0.0)                 | 0.0<br>(-11.1, 16.7) |
| ApoC-II, mg/L  | 34<br>(26, 44)        | 34<br>(26, 45)        | 29<br>(22, 38)       | 34<br>(26, 45)        | -4<br>(-10, 1)                      | 0<br>(-6, 6)          | -13.9<br>(-28.2, 3.7)                 | 0.0<br>(-16.1, 19.4) |
| ApoC-III, mg/L | 85<br>(65, 112)       | 86<br>(65, 114)       | 74<br>(56, 97)       | 87<br>(66, 117)       | -10<br>(-27, 4)                     | 2<br>(-14, 18)        | -13.2<br>(-28.7, 6.5)                 | 2.2<br>(-15.7, 24.4) |
| ApoE, mg/L     | 23<br>(19, 28)        | 23<br>(19, 28)        | 16<br>(12, 20)       | 23<br>(19, 29)        | -7<br>(-11, -3)                     | 0<br>(-3, 4)          | -31.6<br>(-43.5, -17.4)               | 0.0<br>(-13.0, 16.7) |

Values are medians (interquartile range) for continuous variables.



**Figure 1: Clinical performance of prediction models on MACE and all-cause death.** ROC curves of clinical performance for MACE (top) and all-cause death (bottom) based on the prognostic models based on: the apolipoprotein panel (left) consisting of baseline apolipoproteins and ApoE phenotype, the lipid panel (center) consisting of baseline TC, HDL-C, and triglycerides, and the combination of the two panels (right).

The apolipoproteins that significantly contributed to the prognostic full apolipoprotein panel model for MACE, as indicated by the partial Wald tests, are: Apo(a) (linear relationship,  $p < 0.0001$ ), ApoB (linear relationship,  $p < 0.001$ ), ApoC-I (linear relationship,  $p < 0.05$ ), ApoA-II (inverse relationship,  $p < 0.0001$ ), and ApoA-IV (linear relationship,  $p < 0.0001$ ). For all-cause death, ApoA-II (inverse relationship,  $p < 0.0001$ ), ApoA-IV (J-shape relationship,  $p < 0.0005$ ), ApoC-II (inverse relationship,  $p < 0.005$ ) and ApoE (inverse J-shape,  $p < 0.05$ ) significantly contributed to the full apolipoprotein panel model. Models created based on individual apolipoproteins showed only marginal discrimination for predicting MACE or all-cause death, as indicated by their AUCs (Supplemental Figure S4 and S5). Splines of the individual apolipoproteins are shown in Supplemental Figure S6 and S7. A model incorporating the apolipoprotein panel alongside age, sex, ethnicity, body mass index, smoking status and history of diabetes alongside had a significantly better goodness-of-fit than a model using only these readily available variables ( $p < 0.0001$ ).

## Predictive Performance


### Baseline Apolipoprotein Panel Predicts Treatment Benefit of Alirocumab on MACE and All-cause Death

Clinical effectiveness for MACE and all-cause death was evaluated based on baseline apolipoprotein levels of the placebo group (5,926 patients) and the alirocumab group (5,917 patients). The results of the estimated probabilities during a median follow-up of 2.9 years by the apolipoprotein panel per patient for the full study group are shown in Figure 2A. For comparison, the probabilities estimated with the lipid panel and with the lipid and apolipoprotein panels combined are presented in Supplemental Figure S8 and S9.

With higher baseline risk for MACE as estimated by the apolipoprotein panel, a larger number of patients had a lower calculated probability of an event with alirocumab than with placebo, indicating that the apolipoprotein panel can predict a treatment benefit of alirocumab on MACE (Figure 2A). The same trend is observed for prediction models based on the conventional lipid panel and the combination of the two panels (Supplemental Figure S8). For all-cause death a comparable pattern emerged, with individuals at higher estimated baseline risk having a lower estimated probability of an event when allocated to alirocumab (Figure 2C).

Using the observed overall 2.1% absolute reduction in risk of MACE with alirocumab as a minimum criterion for treatment benefit, two subgroups were defined based on the baseline apolipoprotein panel: those with a benefit from alirocumab treatment ( $n = 5,045$ ) and those without ( $n = 6,798$ ) (Figure 2B). A similar dichotomization was performed for all-cause death, using the observed overall 0.7% absolute reduction in risk of all-cause death with alirocumab as the threshold. A total of 4,384 patients had a risk reduction of 0.7% or more, while 7,459 patients fell below this threshold.

Figure 2B and 2D show the classification of benefit versus no benefit, using the predefined thresholds, for different baseline risks, as calculated with the apolipoprotein panels. In a relative sense, more were found to benefit from alirocumab treatment in those at a higher calculated baseline risk of a cardiovascular event. Analogous distributions of benefit versus no benefit based on the lipid panel and the combination of the lipid and apolipoprotein panels are shown in Supplemental Figure S8.




**Figure 2: Model-based calculated risk fraction in the placebo respectively targeted treatment group of the apolipoprotein panel for MACE and all-cause death.** Panel A for MACE and C for all-cause death display scatter plots of model-based calculated risk if allocated to placebo or allocated to alirocumab. Panel B and D present the stacked distribution of risk in the subgroups defined to achieve meaningful benefit or not for MACE and all-cause death (absolute risk reduction with alirocumab of 2.1% or higher for MACE and 0.7% or higher for all-cause death). Risk is calculated based on the apolipoprotein panel.

## Treatment Benefit of Alirocumab as Estimated by the Apolipoprotein Panel Prediction Model

The results of estimating treatment benefit of alirocumab for reducing the risk of MACE or all-cause death based on apolipoproteins can help identify the subgroup most likely to benefit from treatment. For instance, if one were willing to treat only those with an estimated absolute MACE risk above 8%, 73% of the cohort would be treated, which would be 95% of those with a calculated treatment benefit and 55% of those without. (Figure 3A). In contrast, if the clinical decision threshold to treat with alirocumab was set at a higher estimated risk, 17% (Figure 3B), only 16% would be treated: 31 of those with a calculated benefit but only 5% of those without.

Figure 3C shows these proportions for other probability thresholds. For clinical decision making an example of probability thresholds is shown in Figure 3D, where increasing the threshold means decreasing the sensitivity, but increasing the specificity of the apolipoprotein panel test.



**Figure 3: Probability thresholds for treatment allocation based on estimated treatment benefit by the apolipoprotein panel.** Panel A and B show the clinical decision limit at 8% and 17% estimated risk of MACE and the resulting sensitivity and specificity, respectively. Panel C shows the sensitivity or specificity at specific probability thresholds. Panel D shows a table with five examples of probability thresholds and the resulting sensitivity, and specificity.

## DISCUSSION

In this study, we assessed the clinical performance and clinical effectiveness of a comprehensive 9-plex apolipoprotein panel in a subset of the ODYSSEY OUTCOMES trial participants, comprised of patients with recent ACS on optimized statin therapy. The baseline apolipoprotein panel led to better and incremental classification of MACE and all-cause death, compared with the conventional lipid panel. The apolipoprotein panel was also able to predict treatment benefit of alirocumab on MACE and all-cause death.

Our results further demonstrate that individual apolipoproteins were not prognostic for MACE or all-cause death in this population, suggesting that interdependent apolipoproteins should preferably be measured as a full panel to predict cardiovascular events. In the full apolipoprotein panel model, the partial effects of each apolipoprotein, adjusted for other variables, significantly

contributed to the prediction of MACE according to the partial Wald tests. Specifically, Apo(a), ApoB, ApoC-I, and ApoA-IV demonstrated a positive linear relationship with MACE, while ApoA-II exhibited an inverse relationship. For all-cause death, the apolipoproteins that significantly contributed to the full panel model were ApoA-II and ApoC-II, which demonstrated an inverse relationship, ApoA-IV, which showed a J-shaped relationship, and ApoE, which exhibited an inverse J-shaped relationship (all  $p < 0.05$ ).

Several of the apolipoproteins in our panel are well-established risk factors. Apo(a) is recognized as an important cardiovascular risk factor as supported by Mendelian randomization studies<sup>38, 39</sup>, epidemiological evidence<sup>40</sup>, and cardiovascular outcome trials.<sup>17, 41, 42</sup> Similarly, ApoB, another contributing predictor, is a well-established cardiovascular risk factor as well and its measurement is recommended for cardiovascular risk assessment.<sup>9, 14, 43, 44</sup> ApoC-I plays a dual role in lipid metabolism, acting as either atherogenic by inhibiting triglyceride-rich lipoprotein metabolism or atheroprotective by facilitating HDL synthesis and stabilization.<sup>6</sup>

ApoA-II and ApoA-IV made significant contributions to the prediction models for both outcomes according to the partial Wald tests. The role of ApoA-II in cardiovascular disease remains poorly understood, with conflicting findings in the literature.<sup>25, 45-47</sup> In the present study, spline analysis in this ACS cohort on optimized statin therapy revealed an inverse relationship between ApoA-II concentrations and the likelihood of MACE and all-cause death, indicating that lower ApoA-II levels may increase the risk of adverse cardiovascular outcomes (Supplemental Figure S2 and S3). Interestingly in the present study, ApoA-IV, which is generally considered a cardioprotective factor, was associated with MACE (linear relationship) and all-cause death (J-shape) (Supplemental Figure S2 and S3). This is in contrast with findings from the PROCARDIS study, where ApoA-IV, as part of an apolipoprotein panel, was inversely associated with coronary heart disease.<sup>25</sup> The reasons behind the conflicting results for ApoA-IV need further investigation to understand the underlying mechanisms.

ApoE plays a crucial role in lipid metabolism and cardiovascular disease risk, particularly through its involvement in the clearance of remnant lipoproteins. ApoC-II, on the other hand, is essential for activating lipoprotein lipase, promoting the metabolism of triglyceride-rich lipoproteins, and its inverse association with all-cause death in this study suggests a protective role. ApoC-I and ApoC-III are associated with the risk of cardiovascular events which is also demonstrated in the current study. For ApoC-III this can be explained by the fact that it acts as an inhibitor of lipolysis and impairs the clearance of triglyceride-rich lipoproteins, leading to the accumulation of these atherogenic particles in circulation.<sup>6</sup> ApoC-I plays a dual role and can act as an inhibitor of lipolysis, which explains the association with MACE demonstrated in this study with its linear relationship with MACE and all-cause death.<sup>6</sup>

Some potential limitations of our analysis should be acknowledged. It is important to note that this was a post hoc analysis in a subgroup from a randomized clinical trial. Nevertheless, the characteristics of the analysis cohort were generally representative of the full trial cohort. Ideally, the clinical effectiveness of a new medical test should be evaluated using direct outcome data in a comparative randomized controlled trial. This would involve a study comparing lipids and apolipoproteins in separate arms of the trial, assessing the impact on patient outcomes based on management guided by the test results. However, such a study design is challenging and very expensive. In the current study, we adopted an alternative approach in which we measured apolipoprotein levels and developed prognostic and predictive models based on these levels, comparing them with predictions made using the conventional lipid panel.

We developed and evaluated multivariable prediction models in a single study group and did not rely on a separate validation cohort for obtaining independent estimates of performance. While this does not jeopardize the validity of our comparison of models based on either lipids, apolipoproteins or their combination, it may mean that performance of each of the three models is overestimated, compared to what would have been obtained in an independent evaluation of performance.

There are numerous apolipoproteins, of which we carefully selected nine for measurement in the context of cardiovascular disease.<sup>6,8</sup> Not measuring all apolipoproteins may present a limitation, as it leaves uncertainty regarding whether these selected apolipoproteins provide the greatest amount of prognostic or predictive information.

The ODYSSEY OUTCOMES Trial recruited from a population with established cardiovascular disease, which allowed us to assemble a large, multinational cohort for assessing clinical and predictive performance of apolipoprotein profiling. Performance in other populations and for other testing purposes is still unknown. In general, clinical performance will differ, according to the testing purpose, the target population, target condition or event, and with other comparator index tests.

The study group for our analyses was highly selected, as a result of the trial inclusion criteria, which focused on inadequate control of ApoB-containing lipoproteins, reflected in levels of LDL-C and non-HDL-C, while excluding patients with markedly elevated triglyceride levels. Consequently, patients with pronounced elevations of remnant lipoproteins, a condition often underdiagnosed in current clinical practice, were likely excluded. It is possible that the apolipoprotein panel has particular value in remnant disease.<sup>4,8</sup> Nearly 90% of the current analysis cohort was treated with high-intensity statin therapy, which might have curbed the prognostic and predictive performance of the apolipoprotein panel.

The apolipoprotein panel was able to predict treatment benefit with alirocumab for MACE. These results suggest that the apolipoprotein panel can be used to identify patients more likely to benefit from addition of a PCSK9 inhibitor to statin. Based on the risk of MACE estimated with the apolipoprotein panel, physicians might select individuals who are at a sufficiently high estimated risk and more likely to benefit from treatment, while not treating patients at a lower estimated risk and lower expected benefit of treatment. This personalized approach might enhance the cost-effectiveness of treatment.

We speculate that the predictive performance of the apolipoprotein panel in estimating treatment benefit of therapies that directly target a single apolipoprotein may be even stronger than observed in the current analysis for alirocumab. For example, it is possible that apolipoprotein profiling could help guide the selection of patients for therapies in development that specifically target Apo(a)<sup>23, 48</sup> or ApoC-III<sup>49, 50</sup>.

In addition to treatment decisions, apolipoprotein profiling could serve as a valuable tool for precision diagnostics and personalized medicine, enabling a more refined diagnosis of dyslipidemia beyond the traditional classification based on lipids and potentially uncover novel dyslipidemic phenotypes. Specifically, the comprehensive biomarker panel integrates the interdependencies between the apolipoproteins and by “thinking in wholes” this multiplex approach improves clinical performance and clinical effectiveness of testing.

## CONCLUSION

In patients with recent ACS receiving optimized or maximum-tolerated statin treatment, a 9-plex comprehensive apolipoprotein panel including ApoE phenotype significantly improved classification for MACE and all-cause death beyond the conventional lipid panel. In addition, the apolipoprotein panel may help select patients most likely to benefit from treatment with PCSK9 inhibition therapy versus standard statin therapy. Hence, the 9-plex apolipoprotein panel may be a valuable asset for cardiovascular precision diagnostics and personalized cardiovascular disease.

## ACKNOWLEDGMENTS

The authors thank the patients, study coordinators, and investigators who participated in this trial. Additionally, the authors express their gratitude towards F. Arslan, J.J.J. Georges, M.M. Pieterse, N.P.M. Smit, N.M. Diederiks, M.M. Treep, and A. van der Laarse for their contribution.

## DISCLOSURES

Ms. Reijnders reports no disclosures. Dr. Bossuyt discloses the following relationships – Advisory Board: Netherlands Healthcare Institute, Owlstone; Editorial Board: Radiology, Clinical Chemistry; Funding Committees: Cancer Research UK Early Detection, Dutch Cancer Foundation Biomarkers, Belgium-Netherlands Funding of International Trials, Independent Research Fund Denmark. Dr. Jukema has received research grants from and/or was speaker (with or without lecture fees) on a.o.(CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera,, Biotronik, Boston Scientific, Dalcour, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, The Netherlands Heart Foundation, CardioVascular Research The Netherlands (CVON), The Netherlands Heart Institute and the European Community Framework KP7 Programme. Dr. Ruhaak reports no disclosures. Mr. Romijn reports no disclosures. Dr. Szarek receives salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado, that receives or has received research grant/consulting funding between July 2021 and July 2024 from the following organizations: Abbott Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma Godo Kaisha, Amgen Inc., Anthos Therapeutics, Inc., ARCA biopharma, Inc., Arrowhead Pharmaceuticals, AstraZeneca Pharma India, AstraZeneca UK Ltd, Bayer, Bayer Aktiengesellschaft, Bayer Pharma AG, Beth Israel Deaconess Medical Center, Better Therapeutics, Boston Clinical Research Institute, LLC, Bristol-Myers Squibb, Cleerly, Inc., Colorado Dept of Public Health and Environment, Congress Inc, Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EPG Communication Holdings Ltd., Esperion Therapeutics, Inc, Faraday Pharmaceuticals, Inc., HeartFlow Inc, Insmad, Ionis Pharmaceuticals, IQVIA Inc., Janssen Pharmaceuticals, Inc, Janssen Research & Development, LLC, Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals, Inc., Medpace, Inc., Medscape, Merck Sharp & Dohme Corp., Nectero Medical, Inc, Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Pfizer, PPD Development, L.P., Prothena Biosciences Limited, Regeneron, Regents of the University of Colorado (aka UCD), Sanifit Therapeutics S.A., Sanofi, Silence Therapeutics PLC, Stanford University, Stealth BioTherapeutics Inc., The Brigham and Women's Hospital, Thrombosis Research Institute, Tourmaline Bio, Inc, University of Colorado, University of Colorado Denver, University of Pittsburgh, VarmX, Verve Therapeutics, WraSer, LLC. Michael Szarek serves as a consultant for and/or has received research support from Lexicon, Amarin, NewAmsterdam, Silence, Sanofi, Regeneron Pharmaceuticals, and Tourmaline. Dr. Trompet reports no disclosures.. Dr. Bhatt discloses the following relationships - Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys; Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock); Consultant: Broadview Ventures,

GlaxoSmithKline, Hims, SFJ, Youngene; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald's Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo. Dr. Bitnner reports to have completed contracts between UAB and sponsor: DalCor, Esperion – National Coordinator, and ongoing contracts between UAB and

sponsor: Amgen - EVOLVE MI (site PI), Novartis – ORION (site PI), Wake Forest Health (NIA subcontract): RehabHFpEF, and past contract between UAB and sponsor: Sanofi and Regeneron: OO and UAB contract ended in 2018/9, but publications are ongoing. Furthermore she Consultant: New Amsterdam Pharma, Pfizer (both completed, but within the 3 year time frame). DSMB (ongoing): Eli Lilly; Verve Therapeutics. Dr Diaz reports research grants from Sanofi, DalCor Pharmaceuticals, Population Health Research Institute, Duke Clinical Research Institute, the TIMI group, Amgen, Cirius, Montreal Health Innovations Coordinating Center, and Lepetit; and personal fees, as a member of the Executive Steering Committee, from Amgen and Cirius. . Dr. Fazio is an employee of Regeneron Pharmaceuticals, Inc.. Ms. Garon is an employee of Sanofi and may hold shares in the company. Dr. Goodman received research grant support (e.g., steering committee or data and safety monitoring committee) and/or is speaker/consulting honoraria (e.g., advisory boards) from: Alnylam, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, CYTE Ltd., Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, Idorsia, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Roche, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma; and salary support/honoraria from the Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, Jewish General Hospital\ CIUSSS Centre-Ouest-de-l'Île-de-Montreal, New York University Clinical Coordinating Centre, PERFUSE Research Institute, Peter Munk Cardiac Centre Clinical Trials and Translation Unit, Ted Rogers Centre for Heart Research, TIMI Study Group (Brigham Health). Dr. Harrington reports research grants /contracts (active) RCT: NHLBI (ISCHEMIA), Duke/PCORI (ADAPTABLE), Janssen (Factor XIa inhibitor), CSL (HDL) and DSMB: Baim Institute, UColorado, Harvard/BWH (TIMI). Consulting and advisory roles for NHLBI (COVID/CONNECTS), Atropos Health, Azurna, Basking Bioscience, Bitterroot Bio, BMS, Bridge Bio, Chiesi, Colorado Prevention Center, CSL Behring, Edwards Lifesciences Corp, Element Science, Foresight, Merck, WebMD and is part of the board of directors for AHA, Cytokinetics. Dr. White has received grant support paid to the institution and fees for serving on Steering Committees from Sanofi-Aventis, Regeneron Pharmaceuticals, Omthera Pharmaceuticals, American Regent, DalCor Pharma UK, Inc., CSL Behring, National Health Institutes, Sanofi-Aventis Australia Pty Ltd, Janssen Research and Development LLC, Esperion Therapeutics, Inc and National Institutes of Health. Dr. Steg reports research grants from Amarin, AstraZeneca, Bayer. Consulting for Amarin, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Janssen, Pfizer, PhaseBio, Novartis, NovoNordisk, Regeneron, Sanofi, Servier and has a patent issued as co inventor of use of alirocumab to reduce cardiovascular risk (patent assigned to Sanofi). Dr. Schwartz has received research support to the University of Colorado from AstraZeneca, Sanofi, and Silence Therapeutics. Support for travel to trial meetings from the University of Oxford. Dr. Cobbaert reports research collaboration with Roche Diagnostics

## SOURCES OF FUNDING

This work was supported by Sanofi and Roche Diagnostics. Apolipoprotein measurements were conducted on a 6495 QQQ-MS loan instrument from Agilent, as part of a research collaboration between Agilent and the Department Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.

## REFERENCES

1. Reijnders E, van der Laarse A, Jukema JW and Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. *Front Cardiovasc Med*. 2023;10:1264319.
2. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. *J Am Coll Cardiol*. 2005;46:1225-8.
3. Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Borén J, Baum H, Bruckert E, Catapano A, Descamps OS, von Eckardstein A, Kamstrup PR, Kolovou G, Kronenberg F, Langsted A, Pulkki K, Rifai N, Sypniewska G, Wiklund O and Nordestgaard BG. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. *Clinical chemistry*. 2018;64:1006-1033.
4. Sandesara PB, Virani SS, Fazio S and Shapiro MD. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. *Endocr Rev*. 2019;40:537-557.
5. Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen M-R, Tokgözoğlu LS, Tybjaerg-Hansen A, Stock JK and Catapano AL. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. *European Heart Journal*. 2021;42:4791-4806.
6. Reijnders E, van der Laarse A, Ruhaak LR and Cobbaert CM. Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling. *Clinical Proteomics*. 2024;21.
7. Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G and Pencina MJ. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. *European Heart Journal*. 2024;ehae258.
8. Ruhaak LR, van der Laarse A and Cobbaert CM. Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. *Ann Clin Biochem*. 2019;56:338-356.
9. Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM and Schwartz GG. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. *Circulation*. 2022;146:657-672.
10. Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, Ference B, Stein E, Stroes ES, Braunwald E, Ellinor PT, Lubitz SA, Ruff CT and Sabatine MS. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. *JAMA Cardiol*. 2022;7:250-256.
11. Contois JH, Langlois MR, Cobbaert C and Sniderman AD. Standardization of Apolipoprotein B, LDL-Cholesterol, and Non-HDL-Cholesterol. *J Am Heart Assoc*. 2023;12:e030405.
12. Langlois MR and Sniderman AD. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? *Curr Cardiol Rep*. 2020;22:67.
13. Bittner V. Apolipoprotein B versus non-high-density lipoprotein cholesterol: is the debate really over? *European Journal of Preventive Cardiology*. 2022;29:2372-2373.
14. Johannesen CDL, Mortensen MB, Langsted A and Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. *J Am Coll Cardiol*. 2021;77:1439-1450.
15. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R and Nordestgaard BG. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. *JAMA*. 2009;301:2331-2339.

16. Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, Ruhaak LR, Schwertfeger M, Tsimikas S, White HD, Steg PG, Cobbaert C, Schwartz GG and Investigators OO. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. *Circulation*. 2024;149:192-203.
17. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, Committees OO and Investigators. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. *J Am Coll Cardiol*. 2020;75:133-144.
18. Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Murphy SA, Goodrich EL, Zhang S, Gaudet D, Karwowska-Prokopczuk E, Tsimikas S, Giugliano RP and Sabatine MS. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. *N Engl J Med*. 2024.
19. Stroes ESG, Alexander VJ, Karwowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, Soran H, Prohaska TA, Xia S, Ginsberg HN, Witztum JL and Tsimikas S. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. *N Engl J Med*. 2024.
20. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. *J Am Coll Cardiol*. 2017;69:692-711.
21. Melita H, Manolis AA, Manolis TA and Manolis AS. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. *J Cardiovasc Pharmacol*. 2022;79:e18-e35.
22. Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ESG, Yu R, Flaim JD, Su J, Stein EA and Kastelein JJP. Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia. *Am J Cardiol*. 2010;105:1413-1419.
23. Yeang C, Karwowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL and Tsimikas S. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. *J Am Coll Cardiol*. 2022;79:1035-1046.
24. Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, Oberhollenzer F, Egger G, Witztum JL, Alexander VJ, Willeit J, Kiechl S and Mayr M. Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III. *Journal of the American College of Cardiology*. 2017;69:789-800.
25. Clarke R, Von Ende A, Schmidt LE, Yin X, Hill M, Hughes AD, Pechlaner R, Willeit J, Kiechl S, Watkins H, Theofilatos K, Hopewell JC and Mayr M. Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease. *Circ Res*. 2023;132:452-464.
26. van den Broek I, Romijn FP, Nouta J, van der Laarse A, Drijfhout JW, Smit NP, van der Burgt YE and Cobbaert CM. Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping. *Clin Chem*. 2016;62:188-97.
27. Ruhaak LR, Smit NPM, Suchiman HED, Pieterse MM, Romijn F, Beekman M and Cobbaert CM. MS-based proteomics: a metrological sound and robust alternative for apolipoprotein E phenotyping in a multiplexed test. *Clin Chem Lab Med*. 2019;57:e102-e104.
28. Ruhaak LR, Smit NPM, Romijn F, Pieterse MM, van der Laarse A, van der Burgt YEM and Cobbaert CM. Robust and Accurate 2-Year Performance of a Quantitative Mass Spectrometry-Based Apolipoprotein Test in a Clinical Chemistry Laboratory. *Clin Chem*. 2018;64:747-749.
29. Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, Monaghan PJ, Verhagen-Kamerbeek WD, Ebert C and Bossuyt PM. From biomarkers to medical tests: the changing landscape of test evaluation. *Clin Chim Acta*. 2014;427:49-57.
30. Diederiks NM, Ruhaak LR, Romijn F, Pieterse MM, Smit NPM and Cobbaert CM. An LC-MS-based designated comparison method with similar performance to the Lp(a) reference measurement procedure to guide molar Lp(a) standardization. *Clin Proteomics*. 2024;21:5.

31. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A and Steg PG. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. *Am Heart J*. 2014;168:682-9.
32. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, Committees OO and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N Engl J Med*. 2018;379:2097-2107.
33. Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG, Committees OO and Investigators. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. *J Am Coll Cardiol*. 2019;73:387-396.
34. Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical chemistry*. 1972;18:499-502.
35. Reijnders E, Romijn FPHTM, Arslan F, Georges JJJ, Pieterse MM, Schipper ER, Didden-Buitendijk S, Martherus-Bultman MC, Smit NPM, Diederiks NM, Treep MM, Jukema JW, Cobbaert CM and Ruhaak LR. Quality Assurance for multiplex Quantitative Clinical Chemistry Proteomics in Large Clinical Trials. *Journal of Applied Laboratory Medicine*. 2024.
36. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Nilsson G, Shamburek RD, Vetrovec GW, Warnick GR and Remaley AT. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. *Clinical chemistry*. 2010;56:977-86.
37. E. HF. *Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis*: Springer International Publishing; 2015.
38. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjaerg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS and Danesh J. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. *JAMA Cardiol*. 2018;3:619-627.
39. Lamina C and Kronenberg F. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. *JAMA Cardiol*. 2019;4:575-579.
40. Nordestgaard BG and Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res*. 2016;57:1953-1975.
41. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR and Sabatine MS. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. *Circulation*. 2019;139:1483-1492.
42. Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A and Tsimikas S. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet*. 2018;392:1311-1320.
43. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A and Ference BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. *JAMA Cardiol*. 2019;4:1287-1295.

44. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglul L, Wiklund O, Windecker S, Aboyans V, Baigent C, Collet J-P, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Jung B, Jüni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Nibouche D, Zelveian PH, Siostrzonek P, Najafov R, van de Borne P, Pojskic B, Postadzhiyan A, Kypris L, Špinar J, Larsen ML, Eldin HS, Viigimaa M, Strandberg TE, Ferrières J, Agladze R, Laufs U, Rallidis L, Bajnok L, Gudjónsson T, Maher V, Henkin Y, Gulizia MM, Mussagaliyeva A, Bajraktari G, Kerimkulova A, Latkovskis G, Hamoui O, Slapikas R, Visser L, Dingli P, Ivanov V, Boskovic A, Nazzi M, Visseren F, Mitevska I, Retterstøl K, Jankowski P, Fontes-Carvalho R, Gaita D, Ezhov M, Foscoli M, Giga V, Pella D, Fras Z, Perez de Isla L, Hagström E, Lehmann R, Abid L, Ozdogan O, Mitchenko O and Patel RS. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Atherosclerosis*. 2019;290:140-205.
45. Florea G, Tudorache IF, Fuior EV, Ionita R, Dumitrescu M, Fenyo IM, Bivol VG and Gafencu AV. Apolipoprotein A-II, a Player in Multiple Processes and Diseases. *Biomedicines*. 2022;10:1578.
46. Xiao J, Zhang F, Wiltshire S, Hung J, Jennens M, Beilby JP, Thompson PL, McQuillan BM, McCaskie PA, Carter KW, Palmer LJ and Powell BL. The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population. *Atherosclerosis*. 2008;199:333-9.
47. Deeb SS, Takata K, Peng RL, Kajiyama G and Albers JJ. A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. *Am J Hum Genet*. 1990;46:822-7.
48. O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H and Sabatine MS. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. *N Engl J Med*. 2022;387:1855-1864.
49. Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L and Bruckert E. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. *N Engl J Med*. 2019;381:531-542.
50. Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J and Gaudet D. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. *N Engl J Med*. 2024;390:531-42.

SUPPLEMENTAL INFORMATION

Table S1: Incidence of MACE, cardiovascular death and all-cause death

|                 | Alirocumab (5,917) | Placebo (5,926) | ARR (%) | Total |
|-----------------|--------------------|-----------------|---------|-------|
| MACE            | 596 (10.1%)        | 721 (12.2%)     | 2.1     | 1317  |
| All-cause Death | 208 (3.5%)         | 250 (4.2%)      | 0.7     | 458   |

Values are n (%).







Figure S1: Baseline apolipoprotein levels. Distribution of baseline apolipoprotein concentrations as part of the apolipoprotein panel in the Odyssey Outcomes trial stratified by sex. Placebo and alirocumab are combined (n = 11,843)




**Figure S2: Spline analysis apolipoprotein profile for MACE.** Results of spline analysis of baseline apolipoproteins within the apolipoprotein panel model, based on the placebo group (n = 5,926), adjusted for other apolipoproteins in the model, to predict MACE.




**Figure S3: Spline analysis apolipoprotein profile for all-cause death.** Results of spline analysis of baseline apolipoproteins within the apolipoprotein panel model, based on the placebo group (n = 5,926), adjusted for other apolipoproteins in the model, to predict all-cause death.




**Figure S4: Individual apolipoproteins prognosis of MACE.** ROC curves of nine prediction models based on individual baseline apolipoproteins to the placebo group predict MACE.




**Figure S5: Individual apolipoproteins prognosis of all-cause death.** ROC curves of nine prediction models based on individual baseline apolipoproteins of the placebo group to predict all-cause death.




**Figure S6: Spline analysis individual apolipoproteins for MACE.** Results of spline analysis of individual baseline apolipoproteins, based on the placebo group (n = 5,926) to predict MACE.



**Figure S7: Spline analysis individual apolipoproteins for all-cause death.** Results of spline analysis of individual baseline apolipoproteins, based on the placebo group (n = 5,926) to predict all-cause death.



**Figure S8: Estimated Treatment Effect and Treatment Benefit MACE by Lipid Profile and Lipid Profile in combination with Apolipoprotein Profile.** On the left scatter plots of model-based calculated risk if allocated to placebo or allocated to alirocumab. The plots on the right show the stacked distribution of risk in the subgroups defined to achieve meaningful benefit or not for MACE (absolute risk reduction with alirocumab of 2.1% or higher). Risk is calculated based on the lipid panel and the combination of the lipid panel and the apolipoprotein panel.



**Figure S9: Estimated Treatment Effect and Treatment Benefit all-cause death by Lipid Profile and Lipid Profile in combination with Apolipoprotein Profile.** On the left scatter plots of model-based calculated risk if allocated to placebo or allocated to alicumab. The plots on the right show the stacked distribution of risk in the subgroups defined to achieve meaningful benefit or not for all-cause death (absolute risk reduction with alicumab of 0.7% or higher for all-cause death). Risk is calculated based on the lipid panel and the combination of the lipid panel and the apolipoprotein panel.

